Last reviewed · How we verify
integrilin
integrilin is a Small molecule drug developed by University of Cincinnati. It is currently in Phase 1 development for Acute coronary syndrome, NonQ wave myocardial infarction, Percutaneous coronary intervention.
Eptifibatide is an antiplatelet drug that belongs to the class of integrin alpha-IIb/beta-3 inhibitors, which reversibly binds to platelets. It is used to treat conditions such as stroke, acute coronary syndrome, and coronary artery disease, often in combination with other medications like aspirin.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | integrilin |
|---|---|
| Sponsor | University of Cincinnati |
| Target | Integrin alpha-IIb/beta-3 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Approved indications
- Acute coronary syndrome
- NonQ wave myocardial infarction
- Percutaneous coronary intervention
- Unstable angina
Common side effects
Key clinical trials
- Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis (PHASE3)
- Multi-arm Optimization of Stroke Thrombolysis (PHASE3)
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) (PHASE3)
- Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic (PHASE1, PHASE2)
- Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
- Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (PHASE2)
- Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel (PHASE2)
- Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- integrilin CI brief — competitive landscape report
- integrilin updates RSS · CI watch RSS
- University of Cincinnati portfolio CI
Frequently asked questions about integrilin
What is integrilin?
What is integrilin used for?
Who makes integrilin?
What development phase is integrilin in?
What does integrilin target?
Related
- Target: All drugs targeting Integrin alpha-IIb/beta-3
- Manufacturer: University of Cincinnati — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for NonQ wave myocardial infarction
- Indication: Drugs for Percutaneous coronary intervention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing